Rheumatoid ArthritisExpoBiomeNCT04847011
Deciphering the Impact of Exposures From the Gut Microbiome-derived Molecular Complex in Human Health and Disease
A study testing Fasting in people with Rheumatoid Arthritis and Parkinson Disease, run by Andreas Michalsen at 2 sites in Germany.
Trial summary
The ExpoBiome project will analyze the impact of fasting on patients with Parkinsons's Disease (PD) or rheumatoid arthritis (RA) on a clinical level as well as the effect of fasting on their immune system and gut microbiota. Read more about this study
- Who is it for?
- Ages 18 to 79 yearsHealthy volunteers can take part
- Conditions the study is for
- Rheumatoid Arthritis, Parkinson Disease, Healthy
- What is being tested?
- Fasting
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 183 participants
- Where
- 2 sitesGermany
- Study dates
- 21 Apr 2021to 26 Sep 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 79 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- One of the following diagnoses: rheumatoid arthritis (first diagnosis >6 weeks ago and <8 years), parkinson's disease OR healthy volunteer
- Control ("healthy") individuals must be without any evidence of active, known or treated RA, without any evidence of active, known or treated central nervous system disease, and without a known family history of idiopathic PD
- Arthritis in at least one joint
- Control individuals should match the RA or PD individuals as closely as possible, especially their age, sex, and education
- Present written declaration of consent
- Consent to specimen collection and specimen use
- Ability to understand the patient information and willingness to sign the consent form
Who cannot join
- gout or proven bacterial arthritis
- Psychiatric illness that limits understanding of the examination protocol (unable to consent)
- BMI < 18.5
- Pre-existing/current eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years.
- Severe internal diseases (e.g. renal insufficiency with creatinine > 2mg/dl)
- Participation in another study
Show all 11Show fewer
- Existing vegan diet or fasting within the past 6 months
- Pregnancy or breastfeeding
- Chronic inflammatory bowel disease
- Use of antibiotics within the past 12 months
- Presence of anemia
Trial locations and contacts
2 sites in 1 country.
Germany2 sites
Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus
Berlin, 14109
Paracelsus-Elena-Klinik Kassel
Kassel, Hesse, 34128
About this study
The ExpoBiome project will analyze the impact of fasting on patients with Parkinsons's Disease (PD) or rheumatoid arthritis (RA) on a clinical level as well as the effect of fasting on their immune system and gut microbiota. ExpoBiome will combine metagenomics and other "omics" [meta-transcriptomics, meta-proteomics and (meta-)metabolomics], bioinformatic analyses and biostatistics under a systems biology framework to gain new mechanistic insights into microbiome-immune system interactions in the context of chronic diseases with inflammatory signatures.
Besides a one time crossectional study of healthy participants, patients with RA and PD a longitudinal fasting study with two arms (RA and PD) is planned.
Read the detailed description
The human gut microbiome is a complex ecosystem, which contributes essential functions to human physiology. Changes to the microbiome are associated with several chronic diseases characterised by inflammation, including neurodegenerative and autoimmune diseases. Microbiome-derived effector molecules comprising nucleic acids, (poly)peptides and metabolites are present at high levels in the gut but have so far eluded systematic study. This gap in knowledge is limiting mechanistic understanding of the microbiome's functional impact on chronic diseases such as Parkinson's Disease (PD) and rheumatoid arthritis (RA). Here, for the first time a combination of advanced high-resolution methodologies will be integrated to comprehensively identify the constituents of this molecular complex and their impact on the human immune system. First, a quantitative, integrated multi-omic analysis on microbiome samples collected from healthy individuals and patients with newly diagnosed PD or RA will be performes.
Using contextualised prior knowledge (ExpoBiome Map) and machine learning methods, we will identify microbial molecules associated with condition-specific immunophenotypes. Second, the biomarker signature during a model clinical intervention (therapeutic fasting) will be validated and tracked to predict treatment outcomes. Third, microbes and molecules will be screened in personalised HuMiX gut-on-chip models to identify novel anti-inflammatory compounds. By providing mechanistic insights into the molecular basis of human-microbiome interactions, the project will generate essential new knowledge about causal relationships between the gut microbiome and the immune system in health and disease. By facilitating the elucidation of currently unknown microbiome-derived molecules, it will identify new genes, proteins,metabolites and host pathways for the development of future diagnostic and therapeutic applications.
- Conditions
- Rheumatoid Arthritis, Parkinson Disease, Healthy
- Being tested
- Fasting
- Medical subject headings
- Arthritis, Rheumatoid, Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FastingOther
Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
| Study group | Role | What they receive |
|---|---|---|
| RA - longitudinal arm | Experimental | Not described Receives: Other: Fasting |
| PD - longitudinal arm | Experimental | Not described Receives: Other: Fasting |
| RA - crosssectional arm | No intervention | Not described |
| PD - crossectional arm | No intervention | Not described |
| Healthy controls - crosssectional arm | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gut microbiota Characterization
Molecular typing of the gut microbiota using sequencing and high-throughput analysis from stool samples (metagenomics, metatranscriptomics, metaproteomics, metabolomics)
Measured: Change over baseline to 12 months
Secondary outcomes (48)
Resting blood pressure
Measured: Change over baseline to 12 months
Heart rate
Measured: Change over baseline to 12 months
Abdominal circumference
Measured: Change over baseline to 12 months
Waist to Hip Ratio
Measured: Change over baseline to 12 months
Body Mass Index (kg/m2)
Measured: Change over baseline to 12 months
Disease Activity Score 28 (DAS-28-CRP)
Change from Baseline in the DAS-28-CRP, range from 2.0 to 10.0 while higher values meaning a higher disease activity and below of 2.6 meaning remission
Measured: Change over baseline to 12 months
Health Assessement Questionnaire (HAQ)
Change from Baseline in the HAQ, range from 0 to 3 while higher values meaning a higher grade of disability
Measured: Change over baseline to 12 months
Simplified Disease Activity Index Score (SDAI)
Change from Baseline in the SDAI, range from 0 to 86 with assumed range from 0.1 to 10mg/dL for CRP. Higher values mean a higher disease activity and below of 34 meaning remission.
Measured: Change over baseline to 12 months
Hannover Functional Ability Questionnaire (Funktionsfragebogen Hannover, FFbH-R)
Change from Baseline in the FFbH-R, range from 0 to 100 % while higher values meaning a higher grade of functional capacity
Measured: Change over baseline to 12 months
MDS-UPDRS
Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale part I, II, IV (MDS-UPDRS part I, II, IV). Total score range: 0-260 (including the MDS-UPDRS part III), including 4 subcategories. Subcategories are summed to compute the total score. A lower score means a better outcome.
Measured: Change over baseline to 12 months
Parkinson's Disease Sleep Scale-2 (PDSS-2)
The Parkinson's Disease Sleep Scale 2 (PDSS-2) is designed to assess nocturnal disability in Parkinson's disease. The PDSS-2 is a 15 question analog scale that ranks answers from 0 - 4, with 4 being worse. (Question 1 is an exception, where 4 is better and 0 is worse). In addition to an overall assessment of sleep disability three aspects of sleep problems can be obtained; disturbed sleep (total of questions 1-3, 8 and 14), PD-specific nocturnal motor symptoms (total of questions 4-6, 12 and 13), and PD-specific nocturnal symptoms (Total of questions 7, 9-11 and 15).
Measured: Change over baseline to 12 months
Parkinson's Disease Questionnaire-39 (PDQ-39)
The 39 question Parkinson's Disease Questionnaire (PDQ-39) is a patient-reported rating scale for quality of life in Parkinson's disease. Respondents affirm if they have experienced problems due to their disease using a five point scale from never (0 points) to always (4 points, or worse) in doing common activities. The PDQ-39 is comprised of 8 domains: mobility, emotion, activities of daily living, cognition, stigma, social support, communication, bodily discomfort. Total possible range of scores = 0 - 156, with higher scores representing worse severity.
Measured: Change over baseline to 12 months
Non-motor symptoms questionnaire (NMSQ)
The non-motor symptoms (NMS) questionnaire can be given to people affected by Parkinson's in order to aid health and social care professionals to assess their non-motor symptoms.The non-motor symptoms questionnaire is a 30-point, patient-based questionnaire used to determine the non-motor symptoms experienced by the patient during the past month. The points should be totalled to give a score out of 30. A score of under 10 is mild, 10-20 moderate and over 20, severe.
Measured: Change over baseline to 12 months
Non Motor Symptoms Scale (NMSS)
The Non-Motor Symptoms Scale (NMSS) measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease, through 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe). Frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms. A negative change from baseline indicates improvement in symptoms (reduced score).
Measured: Change over baseline to 12 months
Stress questionnaire (Cohen Perceived Stress Scale, CPSS)
Change from Baseline in the CPSS, range from 0 to 4 in each item. Scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the positively stated items and then summing across all scale items, higher values meaning a higher grade of perceived stress.
Measured: Change over baseline to 12 months
Quality of Life questionnaire (WHO-5)
Change from Baseline in the WHO-5, range from 0 to 100 %, higher values meaning a higher grade of well-being
Measured: Change over baseline to 12 months
Hospital Anxiety and Depression Scale (HADS)
Assessing full scale, range 0-42, lower score meaning a better outcome
Measured: Change over baseline to 12 months
Mood questionnaire (Profile of Mood States, POMS)
Change from Baseline in Emotional Distress will be measured using the German Version of the Profile of Mood States (ASTS) short version (19 items, 7-point Likert scale; 0=not at all, 6=extremely). Lower scores indicate more stable mood profiles.
Measured: Change over baseline to 12 months
Sociodemographic Measurements
Age, gender, education level, household income, employment status, marital status, language spoken, complete family history, current and previous illness and co-morbidities, and current medications
Measured: Baseline
Behavioral Factors
Physical inactivity, coffee, health promoting activities via Likert Scales, range from 0 to 5 while higher values meaning a higher grade of agreement
Measured: Change over baseline to 12 months
Dietary Behaviour
Modified FFQ recording dietary behaviour such as mealtimes, frequency of food intake, food preferences, fasting experiences
Measured: Change over baseline to 12 months
Behavioral Factors: alcohol consumption
Number of alcoholic beverages on average per week in the last month
Measured: Change over baseline to 12 months
Behavioral Factors: smoking
Smoking status in packyears
Measured: Baseline
Expectation questions
For fasting on a 5-point likert scale from 1 (nothing at all) to 5 (very strong)
Measured: Baseline
Differential blood count
Measured: Change over baseline to 12 months
Hepatic transaminases (GPT, GOT) and Gamma glutamyl transpeptidase (y-GT)
GPT in units per liter (U/L) GOT (U/L) y-GT (U/L)
Measured: Change over baseline to 12 months
Bilirubine (total, direct, indirect in mg/dL)
Measured: Change over baseline to 12 months
Total protein in grams per liter (g/L)
Measured: Change over baseline to 12 months
Albumine in grams per liter (g/L)
Measured: Change over baseline to 12 months
Creatinine in µmol per liter (µmol/L)
Measured: Change over baseline to 12 months
Estimated glomerular filtration rate (eGFR) in milliliter per minute (mL/min)
Measured: Change over baseline to 12 months
Alcalic Phosphatase in units per liter (U/L)
Measured: Change over baseline to 12 months
Urea in milligrams per deciliter (mg/dL)
Measured: Change over baseline to 12 months
Blood lipids and fasting glucose
- triglycerides (mmol/L)
- total cholesterol (mmol/L)
- LDL (mmol/L)
- HDL (mmol/L)
- fasting glucose (mmol/L)
Measured: Change over baseline to 12 months
HbA1C (mmol/mol Hb, %)
Measured: Change over baseline to 12 months
TSH (mU/L)
Measured: Change over baseline to 12 months
IGF-1 (ng/mL)
Measured: Change over baseline to 12 months
Insulin (mU/L)
Measured: Change over baseline to 12 months
High sensitive CrP (mg/L)
Evaluate change in hs-CrP levels in participants with RA
Measured: Change over baseline to 12 months
Rheumatoid factor (RF, IgM) (U/mL)
Evaluate RF status in participants with RA
Measured: Baseline
Anti-cyclic citrullinated peptide (ACPA) (U/mL)
Evaluate change in ACPA levels in participants with RA
Measured: Change over baseline to 12 months
Zonulin (ng/mL)
Measured: Change over baseline to 12 months
Fatty acid binding protein 2 (FABP2) (pg/mL)
Measured: Change over baseline to 12 months
Plasma Calprotectin (µg/g)
Measured: Change over baseline to 12 months
Fecal Calprotectin (µg/g)
Measured: Change over baseline to 12 months
Phenotyping of immune cells
Determination of cytometric parameters that indicate changes in cell activation or quantitative changes in the absolute and/or relative size of subpopulations (e.g. classical/intermediate/non-classical monocytes, naïve and memory T-cells, B-cell differentiation to plasmablasts/-cells) Gene expression analysis of immune cells with Affymetrix whole genome microarrays and RNAseq to search for transcriptional patterns and markers that help to identify relevant immune cell (sub-)populations, which are not yet included in the cytometric phenotyping screen
Measured: Change over baseline to 12 months
Urine metabolomics (10 ml midstream urine)
Measured: Change over baseline to 12 months
Oral microbiota analysis in saliva
Measured: Change over baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2021
- Study start21 Apr 2021
- Primary completion26 Sep 2023
- Study completion26 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 183 participants (actual)
Sponsor and investigators
- Lead sponsor
- Andreas Michalsen
- Sponsor type
- University, hospital or other
- Collaborators
- University of Luxembourg, Paracelsus Elena Klinik
- Responsible party
- Sponsor-investigator, Andreas Michalsen, Charite University, Berlin, Germany
- Investigators
- Andreas Michalsen, Prof. Dr. med., Principal investigator, Charite - Universitätsmedizin Berlin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04847011
- Sponsor's protocol ID
- ExpoBiome
- Acronym
- ExpoBiome
- Status last verified
- Jan 2024
- First submitted
- 14 Apr 2021
- Last updated
- 29 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: It is not yet known if there will be a plan to make IPD available.
Publications
Hansen B, Laczny CC, Aho VTE, Frachet-Bour A, Habier J, Ostaszewski M, Michalsen A, Hanslian E, Koppold DA, Hartmann AM, Steckhan N, Mollenhauer B, Schade S, Roomp K, Schneider JG, Wilmes P. Protocol for a multicentre cross-sectional, longitudinal ambulatory clinical trial in rheumatoid arthritis and Parkinson's disease patients analysing the relation between the gut microbiome, fasting and immune status in Germany (ExpoBiome). BMJ Open. 2023 Aug 18;13(8):e071380. doi: 10.1136/bmjopen-2022-071380.
PubMed 37597865
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Deciphering the Impact of Exposures From the Gut Microbiome-derived Molecular Complex in Human Health and Disease
- ClinicalTrials.gov ID
- NCT04847011
- Acronym / sponsor ID
- ExpoBiome / ExpoBiome
- Conditions
- Rheumatoid Arthritis, Parkinson Disease, Healthy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 183 participants (actual)
- Lead sponsor
- Andreas MichalsenUniversity, hospital or other
- Collaborators
- University of Luxembourg, Paracelsus Elena Klinik
- Study start
- 21 Apr 2021 (actual)
- Primary completion
- 26 Sep 2023 (actual)
- Study completion
- 26 Sep 2023 (actual)
- First posted
- 15 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The ExpoBiome project will analyze the impact of fasting on patients with Parkinsons's Disease (PD) or rheumatoid arthritis (RA) on a clinical level as well as the effect of fasting on their immune system and gut microbiota. ExpoBiome will combine metagenomics and other "omics" [meta-transcriptomics, meta-proteomics and (meta-)metabolomics], bioinformatic analyses and biostatistics under a systems biology framework to gain new mechanistic insights into microbiome-immune system interactions in the context of chronic diseases with inflammatory signatures.
Besides a one time crossectional study of healthy participants, patients with RA and PD a longitudinal fasting study with two arms (RA and PD) is planned.
Detailed description
The human gut microbiome is a complex ecosystem, which contributes essential functions to human physiology. Changes to the microbiome are associated with several chronic diseases characterised by inflammation, including neurodegenerative and autoimmune diseases. Microbiome-derived effector molecules comprising nucleic acids, (poly)peptides and metabolites are present at high levels in the gut but have so far eluded systematic study. This gap in knowledge is limiting mechanistic understanding of the microbiome's functional impact on chronic diseases such as Parkinson's Disease (PD) and rheumatoid arthritis (RA). Here, for the first time a combination of advanced high-resolution methodologies will be integrated to comprehensively identify the constituents of this molecular complex and their impact on the human immune system. First, a quantitative, integrated multi-omic analysis on microbiome samples collected from healthy individuals and patients with newly diagnosed PD or RA will be performes.
Using contextualised prior knowledge (ExpoBiome Map) and machine learning methods, we will identify microbial molecules associated with condition-specific immunophenotypes. Second, the biomarker signature during a model clinical intervention (therapeutic fasting) will be validated and tracked to predict treatment outcomes. Third, microbes and molecules will be screened in personalised HuMiX gut-on-chip models to identify novel anti-inflammatory compounds. By providing mechanistic insights into the molecular basis of human-microbiome interactions, the project will generate essential new knowledge about causal relationships between the gut microbiome and the immune system in health and disease. By facilitating the elucidation of currently unknown microbiome-derived molecules, it will identify new genes, proteins,metabolites and host pathways for the development of future diagnostic and therapeutic applications.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| RA - longitudinal arm | Experimental | Other: Fasting |
| PD - longitudinal arm | Experimental | Other: Fasting |
| RA - crosssectional arm | No intervention | – |
| PD - crossectional arm | No intervention | – |
| Healthy controls - crosssectional arm | No intervention | – |
Who may qualify
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- One of the following diagnoses: rheumatoid arthritis (first diagnosis >6 weeks ago and <8 years), parkinson's disease OR healthy volunteer
- Control ("healthy") individuals must be without any evidence of active, known or treated RA, without any evidence of active, known or treated central nervous system disease, and without a known family history of idiopathic PD
- Arthritis in at least one joint
- Control individuals should match the RA or PD individuals as closely as possible, especially their age, sex, and education
- Present written declaration of consent
Key exclusion criteria (11 listed)
- gout or proven bacterial arthritis
- Psychiatric illness that limits understanding of the examination protocol (unable to consent)
- BMI < 18.5
- Pre-existing/current eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years.
- Severe internal diseases (e.g. renal insufficiency with creatinine > 2mg/dl)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FastingPatients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. | Other | PD - longitudinal arm, RA - longitudinal arm |
Primary outcome
Gut microbiota Characterization
Time frame: Change over baseline to 12 months
Molecular typing of the gut microbiota using sequencing and high-throughput analysis from stool samples (metagenomics, metatranscriptomics, metaproteomics, metabolomics)
48 secondary outcomes
Resting blood pressure
Time frame: Change over baseline to 12 months
Heart rate
Time frame: Change over baseline to 12 months
Abdominal circumference
Time frame: Change over baseline to 12 months
Waist to Hip Ratio
Time frame: Change over baseline to 12 months
Body Mass Index (kg/m2)
Time frame: Change over baseline to 12 months
Disease Activity Score 28 (DAS-28-CRP)
Time frame: Change over baseline to 12 months
Health Assessement Questionnaire (HAQ)
Time frame: Change over baseline to 12 months
Simplified Disease Activity Index Score (SDAI)
Time frame: Change over baseline to 12 months
Hannover Functional Ability Questionnaire (Funktionsfragebogen Hannover, FFbH-R)
Time frame: Change over baseline to 12 months
MDS-UPDRS
Time frame: Change over baseline to 12 months
Parkinson's Disease Sleep Scale-2 (PDSS-2)
Time frame: Change over baseline to 12 months
Parkinson's Disease Questionnaire-39 (PDQ-39)
Time frame: Change over baseline to 12 months
Non-motor symptoms questionnaire (NMSQ)
Time frame: Change over baseline to 12 months
Non Motor Symptoms Scale (NMSS)
Time frame: Change over baseline to 12 months
Stress questionnaire (Cohen Perceived Stress Scale, CPSS)
Time frame: Change over baseline to 12 months
Quality of Life questionnaire (WHO-5)
Time frame: Change over baseline to 12 months
Hospital Anxiety and Depression Scale (HADS)
Time frame: Change over baseline to 12 months
Mood questionnaire (Profile of Mood States, POMS)
Time frame: Change over baseline to 12 months
Sociodemographic Measurements
Time frame: Baseline
Behavioral Factors
Time frame: Change over baseline to 12 months
Dietary Behaviour
Time frame: Change over baseline to 12 months
Behavioral Factors: alcohol consumption
Time frame: Change over baseline to 12 months
Behavioral Factors: smoking
Time frame: Baseline
Expectation questions
Time frame: Baseline
Differential blood count
Time frame: Change over baseline to 12 months
Hepatic transaminases (GPT, GOT) and Gamma glutamyl transpeptidase (y-GT)
Time frame: Change over baseline to 12 months
Bilirubine (total, direct, indirect in mg/dL)
Time frame: Change over baseline to 12 months
Total protein in grams per liter (g/L)
Time frame: Change over baseline to 12 months
Albumine in grams per liter (g/L)
Time frame: Change over baseline to 12 months
Creatinine in µmol per liter (µmol/L)
Time frame: Change over baseline to 12 months
Estimated glomerular filtration rate (eGFR) in milliliter per minute (mL/min)
Time frame: Change over baseline to 12 months
Alcalic Phosphatase in units per liter (U/L)
Time frame: Change over baseline to 12 months
Urea in milligrams per deciliter (mg/dL)
Time frame: Change over baseline to 12 months
Blood lipids and fasting glucose
Time frame: Change over baseline to 12 months
HbA1C (mmol/mol Hb, %)
Time frame: Change over baseline to 12 months
TSH (mU/L)
Time frame: Change over baseline to 12 months
IGF-1 (ng/mL)
Time frame: Change over baseline to 12 months
Insulin (mU/L)
Time frame: Change over baseline to 12 months
High sensitive CrP (mg/L)
Time frame: Change over baseline to 12 months
Rheumatoid factor (RF, IgM) (U/mL)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2024.
- Derived from this study: PubMed 37597865Hansen B, Laczny CC, Aho VTE, Frachet-Bour A, Habier J, Ostaszewski M, Michalsen A, Hanslian E, Koppold DA, Hartmann AM, Steckhan N, Mollenhauer B, Schade S, Roomp K, Schneider JG, Wilmes P. Protocol for a multicentre cross-sectional, longitudinal ambulatory clinical trial in rheumatoid arthritis and Parkinson's disease patients analysing the relation between the gut microbiome, fasting and immune status in Germany (ExpoBiome). BMJ Open. 2023 Aug 18;13(8):e071380. doi: 10.1136/bmjopen-2022-071380.
- Individual participant dataSharing planned: Undecided. It is not yet known if there will be a plan to make IPD available.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Andreas Michalsen, Prof. Dr. med. principal investigator
Charite - Universitätsmedizin Berlin
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fasting in people with Rheumatoid Arthritis and Parkinson Disease, run by Andreas Michalsen at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gut microbiota Characterization (time frame: Change over baseline to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04847011, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2024.